Introduction
According to Acumen Research and Consulting, the global TNF Inhibitor Drugs market is forecasted to grow at striking CAGR around 0.6% over the forecast time frame and reach around US$ 41 billion by 2026.
TNF inhibitors or factor inhibitors of tumor necrosis are biological medicines extracted from human or animal tissue, most frequently used to prevent inflammating and the development of disease, through a suppression of the inflammatory substance, i.e. the necrosis factor of the tumor, in the body. It is mainly used for the therapy of multiple inflammatory diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. In addition to Adalimumab (Humira), Infliximab (Remicade), Certolizumab (Cimzia), etanercept (Enrel), and more, these TNF inhibitors that are currently approved for the therapy of different inflammatory circumstances.
The report provides analysis of global TNF Inhibitor Drugs market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
Market Insights
New product launches, promising pipelines, increased autoimmune disease incidences and significantly increased customer awareness of the Tumor Necrosis Factor (TNF) are anticipated to drive development. TNF inhibitors are used to suppress TNF cytokine inflammation and, consequently, to treat autoimmune and inflammatory diseases like rheumatoid arthritis, psoriasis, Crohn's, and cancer, for example. TNF inhibitors are investigating the role of TNF in the therapy of metastatic melanomas and locally developed soft tissue sarcomas.
Biosimilars pose a direct inner danger to the biologics in TNF inhibitors markets. Loss of patent exclusivities in different areas paves the way. Moreover, the market has intensely rivaled the inhibitors of Interleukin (IL). In many clinical trials, IL inhibitors are shown to have enhanced safety and effectiveness profiles and to show superior outcomes. There has been a substantial paradigm shift in autoimmune disease therapy caused by targeted biodegradable action and the development of bio-similars. However, consumers are more likely to see beneficial impacts on the dynamics of market demand for cost efficient drugs with better safety and efficiency profiles.
Product Stance
In 2018, Humira was in charge of the product segment with almost half its income. In 2018, Humira produced USD 19.9 billion and remains one of the world's most popular pharmaceutical products. Even if Humira's patent expired in Europe in 2018, its exclusivity in the USA is maintained by 2023. The loss of patent exclusivity will probably lead to declined revenues, but it is expected that Humira will be the leading inhibitor of the TNF products by 2026. The biological wave presents a significant danger to biological products, backed by its cost-effectiveness and similar outcomes in head-to-head clinical trials. Several versions have been introduced of Humira, Enbrel, and Remicade. Erelzi, Inflectra / Remsima, Cyltezo and others are some of the main goods of this study.
Application Stance
Autoimmune disease is a major part of the market share, although other signs such as cancer are tested in the drugs. In 2018, rheumatoid arthritis resulted the application segment with an general income share of 17 percent. The segment of rheumatopoietic arthritis is motivated by a elevated therapy speed and product penetration. The most rapidly increasing application sections over the forecast period are psoriasis and psoriatic arthritis. Increasing disease prevalence, customer awareness backed by government and private awareness-raising campaigns and positive reimbursement policies drive the psoriasis market.
Sales Channel Stance
The biggest share of the market in hospitals in 2018 was motivated mainly by the elevated level of hospital turnover. More than retail pharmacies, most biologics and biomarks are marketed in specialized pharmacies. Specialty pharmacies offer one of the biggest benefits of providing tailored, disease-specific treatment plans for every patient and thereby addressing both economic limitations and achieving better results.
Regional Stance
Due to powerful commercial sales of TNF inhibitors in US, North America resulted the regional landscape in 2018. The existence of important producers, proactive governmental projects, favourable repayment policies and a big patient pool are among the other variables contributing to development. In the forecast period, Asia Pacific is expected to be one of the fastest-growing areas. Biosimilar trends are a major driver of national economic growth in the emerging markets, such as China, India and South Korea. Moreover, general economic development, better health infrastructure, higher disposable earnings and increased consumer awareness will probably lead to regional demand.
In the same vein, Europe was a significant share of the worldwide economy and was followed by North America as a result of the existence of a big, inflammatory geriatric population.
Market Segmentation
Global TNF Inhibitor Drugs Market, By Product
- Simponi/Simponi Aria
- Remicade
- Enbrel
- Cimzia
- Humira
- Biosimilars
Global TNF Inhibitor Drugs Market, By Application
- Psoriatic Arthritis
- Crohn’s Disease
- Rheumatoid Arthritis
- Psoriasis
- Juvenile Idiopathic Arthritis
- Hidradenitis Suppurativa
- Ulcerative Colitis
- Ankylosing Spondylitis
- Others
Global TNF Inhibitor Drugs Market, By Sales Channel
- Online Pharmacies
- Specialty Pharmacies
- Hospital Pharmacies
Global TNF Inhibitor Drugs Market, By Geography
- North America.
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa (MEA)
The market research study on “Tumor Necrosis Factor (TNF) Inhibitor Drugs Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global TNF Inhibitor Drugs market segments with market dynamics and their impact. The report also covers basic technology development policies.
It offers an assessment of the recent industry trends for each sub-segment between 2015 and 2026, and anticipates income development at worldwide, regional and nation levels. For this research, ARC segmented the worldwide TNF Inhibitor Drugs market report on the grounds various segments.
Key Players & Strategies
Some of the key players are Amgen Inc., AbbVie Inc., Pfizer, Inc., Novartis International AG, Johnson & Johnson Services, Inc., UCB S.A. and Merck & co., Inc. Competitive market dynamics arise through strategic initiatives, which include fusion and acquisitions, partnerships and joint ventures.
As regulatory processes become stricter and competitive, fresh products must have a major clinical benefit in terms of safety and efficacy or end-result over current products. This resulted to numerous head-to-head experiments between important market products, like Humira and Remicade, and fresh products or applicants for late-stage pipelines. Through comparative parameter assessment, these experiments determine the superiority of performance.
The sector market leaders have established themselves on the market and appreciate customer brand loyalty. These companies offer a broad variety of products and have a large worldwide distribution system. Small players, particularly in Asian emerging markets, also enter the market. However, the market penetration of fresh entrants will be reduced by strict legislative structure and high quality standards set by market leaders.
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Tumor Necrosis Factor (TNF) Inhibitor Drugs
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market By Product
1.2.2.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate Comparison By Product (2015-2026)
1.2.2.2. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share By Product in 2017
1.2.2.3. Simponi/Simponi Aria
1.2.2.4. Remicade
1.2.2.5. Enbrel
1.2.2.6. Cimzia
1.2.2.7. Humira
1.2.2.8. Biosimilars
1.2.3. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market By Application
1.2.3.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Psoriatic Arthritis
1.2.3.3. Crohn’s Disease
1.2.3.4. Rheumatoid Arthritis
1.2.3.5. Psoriasis
1.2.3.6. Juvenile Idiopathic Arthritis
1.2.3.7. Hidradenitis Suppurativa
1.2.3.8. Ulcerative Colitis
1.2.3.9. Ankylosing Spondylitis
1.2.3.10. Others
1.2.4. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market By Sales Channel
1.2.4.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate Comparison By Sales Channel (2015-2026)
1.2.4.2. Online Pharmacies
1.2.4.3. Specialty Pharmacies
1.2.4.4. Hospital Pharmacies
1.2.5. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market by Geography
1.2.5.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Major Manufacturers in 2017
3.3. R&D Status and Technology Product of Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Major Manufacturers in 2017
CHAPTER 4. TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY PRODUCT
4.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue By Product
4.2. Simponi/Simponi Aria
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Remicade
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Enbrel
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Cimzia
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Humira
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Biosimilars
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY APPLICATION
5.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue By Application
5.2. Psoriatic Arthritis
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Crohn’s Disease
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Rheumatoid Arthritis
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Psoriasis
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Juvenile Idiopathic Arthritis
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Hidradenitis Suppurativa
5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. Ulcerative Colitis
5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.9. Ankylosing Spondylitis
5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.10. Others
5.10.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.10.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY SALES CHANNEL
6.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue By Sales Channel
6.2. Online Pharmacies
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Specialty Pharmacies
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Hospital Pharmacies
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. NORTH AMERICA TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY COUNTRY
7.1. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
CHAPTER 8. EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY COUNTRY
8.1. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
CHAPTER 9. ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY COUNTRY
9.1. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
CHAPTER 10. LATIN AMERICA TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY COUNTRY
10.1. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
CHAPTER 11. MIDDLE EAST TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY COUNTRY
11.1. Middle East Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
CHAPTER 12. AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY COUNTRY
12.1. Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
CHAPTER 13. COMPANY PROFILE
13.1. Amgen Inc.
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. AbbVie Inc.
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Pfizer, Inc.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Novartis International AG
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Johnson & Johnson Services, Inc.
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. UCB S.A.
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Merck & co., Inc.
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Others
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
CHAPTER 14. RESEARCH APPROACH
14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope
